The dataset's assignee ranking shows one company clearly ahead with 65 records, well above the fifth-ranked assignee's 21. The top 5 assignees together hold 182 of the 407 records in scope, or 44.7%, and the top 10 extend that to 63.6%. Beyond that leading group, the ranking includes 98 companies in total, most holding only a small number of families, so the field combines a concentrated top tier with a long tail of narrower filers.

Filings peaked at 41 in 2018, fell to a low of 4 in 2021, and then rebounded sharply to 17 by 2024 — a +325% increase over that three-year span. Because publication typically lags filing by around 18 months, the lower counts shown for 2025 and 2026 are an artefact of incomplete data rather than evidence of a real slowdown. Treated on its own terms, 2024 is the most recent year that can be read as a complete signal, and it points to renewed rather than declining activity.

Medicinal preparations (A61K) and therapeutic activity (A61P) dominate, appearing on 58.7% and 30.5% of the 407 records respectively, reflecting the technique's heavy use in tablet and oral dosage manufacturing. Smaller but real shares also appear in heterocyclic compounds, catalysis and chemical processing, animal feed, powder metallurgy, plastics shaping and additive manufacturing. Anyone working outside pharmaceutical formulation should still check these adjacent classes rather than assume the prior art is limited to drugmakers.

This Glaxo Group filing claims a process for preparing a pharmaceutical composition containing piboserod or a pharmaceutically acceptable salt by forming it into granules through dry granulation, preferably roller compaction followed by milling to a suitable particle size. It is one representative record in a much larger set of process claims covering roller compaction, and its scope is specific to that active compound and its salts rather than to roller compaction generally. Anyone assessing freedom to operate should read its granted claims directly rather than infer scope from the abstract alone.

Relative to the dense core claims around ribbon formation and milling, narrower process-control branches such as roll surface sealing design, fines recycle loop control, nip angle sensing and in-line ribbon density monitoring show thinner filing activity in this dataset. Non-pharmaceutical applications, including continuous granulation for animal feed and granule strength for additive manufacturing feedstock, likewise carry smaller shares of the 407 records. These are reasonable starting points for a dedicated novelty search, though thinner filing density should be confirmed with its own targeted search rather than assumed from the topline classification counts.